Alexion Uses Excess Cash To Buy Strikingly Similar Synageva
This article was originally published in The Pink Sheet Daily
At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.
The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahorta, has resigned from the role at the association after the company breached the ABPI Code of Practice.